13F-HR filed by SUPERSTRING CAPITAL MANAGEMENT LP
SUPERSTRING CAPITAL MANAGEMENT LP filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 30 holding rows worth $140,103,375.
- Accession
- 0001931118-24-000005
- Filer
- CIK 1931118
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 30 entries on the cover page, a total value of $140,103,375 stated on the cover page (in dollars after the unit check, H1), rows summing to $140,103,375 with VALUE read as dollars as filed, 13F file number 028-23866. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| IMMUNOGEN INC | 45253H101 | COMMON STOCK | 598,072 | $17,732,835 | dollars as filed | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 177,603 | $14,828,074 | dollars as filed | |
| 89BIO INC | 282559103 | COM | 1,021,477 | $11,409,898 | dollars as filed | |
| IONIS PHARMACEUTICALS INC COM | 462222100 | Stock | 189,618 | $9,592,775 | dollars as filed | |
| IDEAYA BIOSCIENCES INC COM | 45166A102 | Stock | 251,295 | $8,941,076 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 379,143 | $8,693,749 | dollars as filed | |
| IMMUNOVANT INC | 45258J102 | COM | 203,592 | $8,577,331 | dollars as filed | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 206,326 | $8,329,381 | dollars as filed | |
| Day One Biopharmaceuticals Inc | 23954D109 | Common Stock | 379,626 | $5,542,540 | dollars as filed | |
| MARINUS PHARMACEUTICALS INC | 56854Q200 | COM NEW | 462,444 | $5,026,766 | dollars as filed | |
| NEUROCRINE BIOSCIENCES INC | 64125C109 | COM | 29,346 | $3,866,629 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 255,430 | $3,831,450 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 814,266 | $3,827,050 | dollars as filed | |
| ROIVANT SCIENCES LTD | G76279101 | SHS | 326,161 | $3,662,788 | dollars as filed | |
| LANTHEUS HLDGS INC | 516544103 | COM | 54,896 | $3,403,552 | dollars as filed | |
| FATE THERAPEUTICS INC | 31189P102 | COM | 847,823 | $3,170,858 | dollars as filed | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 74,649 | $2,968,044 | dollars as filed | |
| ACELYRIN INC | 00445A100 | COM | 356,924 | $2,662,653 | dollars as filed | |
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 124,040 | $2,465,915 | dollars as filed | |
| NKARTA INC | 65487U108 | COMMON STOCK | 347,381 | $2,292,715 | dollars as filed | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 16,086 | $1,995,629 | dollars as filed | |
| QUANTERIX CORP | 74766Q101 | COMMON STOCK | 71,760 | $1,961,918 | dollars as filed | |
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 16,179 | $1,287,687 | dollars as filed | |
| SO YOUNG INTERNATIONAL INC | 83356Q108 | SPONSORED ADS | 796,059 | $1,003,034 | dollars as filed | |
| IMMATICS N.V | N44445109 | SHS | 79,213 | $834,113 | dollars as filed | |
| ALLOGENE THERAPEUTICS INC | 019770106 | COM | 222,112 | $712,980 | dollars as filed | |
| INOZYME PHARMA INC | 45790W108 | COM | 123,944 | $528,001 | dollars as filed | |
| FUSION PHARMACEUTICALS INC | 36118A100 | COM | 45,801 | $440,148 | dollars as filed | |
| SPRUCE BIOSCIENCES INC | 85209E109 | COM | 118,814 | $348,125 | dollars as filed | |
| LAKESHORE BIOPHARMA CO LTD | G9845F109 | COM | 307,920 | $165,661 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001931118-24-000005 | this filing | 2024-02-14 | acceptance time not in the bulk data set |